(Q44466715)

3 December 2017

title

Does amifostine have a role in chemoradiation treatment? (English)

1 reference

3 December 2017

0 references

David M Brizel

1

1 reference

3 December 2017

Jens Overgaard

series ordinal

2

1 reference

3 December 2017

publication date

1 June 2003

1 reference

Lancet Oncology Commission

3 December 2017

published in

1 reference

3 December 2017

volume

4

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

378-381

1 reference

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Effective surgical adjuvant therapy for high-risk rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Design and analysis of non-inferiority mortality trials in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Has the outlook improved for amifostine as a clinical radioprotector?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901132-X

7 January 2021

10.1016/S1470-2045(03)01132-X

Identifiers

DOI

1 reference

3 December 2017

1 reference